Cancer clinical trials in the region Occitanie
378 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 3
Multiple myeloma
#NCT05827016
#2022-501515-14-00
Symptomatic multiple myeloma
None
None
Autologous stem cell transplant
Systemic Treatment-Naive
10 recruiting sites
Bristol-Myers Squibb
Phase 3
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT06819007
#2024-516982-35-00
Epithelial ovarian cancer
Fallopian tube cancer
Primary peritoneal cancer (PPC)
Serous high grade carcinoma (HGSOC)
Endometrioid carcinoma
Clear cell carcinoma
Mucinous carcinoma
Other epithelial ovarian cancer
Stage III
Stage IV
Locally Advanced
Metastatic
HER2
None
Chemotherapy
Targeted therapy
BRCA 1/2
10 recruiting sites
Daiichi Sankyo
Phase 3
Amyloidosis
#NCT06128629
#2023-507220-23-00
Other
Presence
Cardiac
5 recruiting sites
Intellia Therapeutics
Phase 3
Amyloidosis
#NCT07207811
#2024-518899-31-00
Other
Presence
Cardiac
19 recruiting sites
Novo Nordisk A/S
Phase 3
Amyloidosis
#NCT06563895
#2024-513547-82-00
Other
Other mutation
None
Systemic Treatment-Naive
Absence
5 recruiting sites
Eidos Therapeutics, a BridgeBio company
Phase 3
Amyloidosis
#NCT07052903
#2024-519917-72-00
Other
Presence
Cardiac
15 recruiting sites
Alnylam Pharmaceuticals
Phase 3
Thyroid and adrenal gland cancer
#NCT04290663
#2024-514603-34-00
Thyroid cancer
Differentiated carcinoma
Localized
None
Systemic Treatment-Naive
Surgery
Radioactive iodine
28 recruiting sites
Centre François Baclesse
Phase 3
Lymphoma
#NCT06911502
B cell lymphoma
Follicular lymphoma
None
> 60 ml/min
1
2
3 or more
Chemotherapy
Monoclonal antibodies
5 recruiting sites
Celgene
Phase 3
Lung cancer
#NCT04613596
#2023-508922-83-00
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
KRAS G12C
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
16 recruiting sites
Mirati Thérapeutique Inc.
Phase 3
Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN)
#NCT06465953
#2023-510155-37
Myelodysplastic syndromes (MDS)
MDS de novo
Secondary MDS
IDH1/2
None
Low
Moderately low
Moderately high
High
Very high
Chemotherapy
Allogeneic stem cell transplant
6 recruiting sites
Servier